Home » Topics » Regulatory » EMA

EMA
RSS

CHMP grants positive opinion for labeling update to Relvar Ellipta in patients with asthma

Jan. 29, 2018

EMA accepts patisiran MAA for hereditary ATTR amyloidosis

Jan. 26, 2018

Santhera anticipates negative CHMP opinion on appeal for MAA for Raxone

Jan. 25, 2018

U.S. priority review and E.U. accelerated assessment granted for Kymriah

Jan. 17, 2018

EMA accepts Evenity MAA in osteoporosis

Jan. 8, 2018

EMA gives orphan drug designation to Spruce Biosciences' SPR-001

Jan. 8, 2018

EMA accepts CMA application for avacopan for ANCA-associated vasculitis

Jan. 4, 2018

Cascadian Therapeutics receives pediatric investigation plan waiver from EMA for tucatinib

Jan. 3, 2018

BiondVax Pharmaceuticals planning phase III study of universal flu vaccine

Dec. 29, 2017

EMA committee recommends against approval of Aplidin for multiple myeloma.

Dec. 19, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.